Nature, evolution, and appraisal of adverse events and antibody response associated with the fifth consecutive dose of a five-component acellular pertussis-based combination vaccine.
We performed a randomized, controlled clinical trial to characterize the evolution of the adverse events associated with the fifth consecutive dose of an acellular pertussis vaccine, and to assess the level of discomfort associated with the injection and the attitude of parents concerning these events. A total of 505 children who had received either four doses of acellular pertussis vaccine or whole-cell pertussis vaccine were given a fifth dose of one of the two vaccines. Adverse events were monitored by parents and collected by telephone or home visit at 4, 8, 12, 24, 48 and 72 h, and 7 and 28 days after immunization. Rates of injection site redness >or=50mm were similar in recipients of five doses of acellular pertussis vaccine (32.8%) or five doses of whole-cell pertussis vaccine (43.3%). Injection site swelling, tenderness, and decreased arm movement were all more frequent in children who received five doses of whole-cell pertussis vaccine. Antibody levels before or after immunization did not predict those children who had increased injection site reactions. The children rated the injection site reactions as significantly more severe after five consecutive doses of whole-cell vaccine. Parent satisfaction was higher after the acellular vaccine. We conclude that a fifth consecutive dose of a whole-cell pertussis vaccine is associated with high rates of tender redness and swelling at the injection site, in contrast to a fifth consecutive dose of an acellular pertussis vaccine which is associated with high rates of non-painful redness. However, parents will still need to be aware of the high rates of injection site reactions expected after a fifth dose of acellular pertussis vaccine.
Halperin
Scott A
SA
Clinical Trials Research Center, Dalhousie University, IWK Health Centre, 5850 University Avenue, 8 West Research, Halifax, NS, Canada B3J 3G9. shalperin@iwkgrace.ns.ca
Scheifele
David
D
Mills
Elaine
E
Guasparini
Roland
R
Humphreys
Garry
G
Barreto
Luis
L
Smith
Bruce
B
D002648:Child; D002675:Child, Preschool; D015721:Diphtheria-Tetanus-Pertussis Vaccine / Q000009:adverse effects*; D004311:Double-Blind Method; D018073:Haemophilus Vaccines / Q000009:adverse effects; D006801:Humans; D007117:Immunization, Secondary / Q000009:adverse effects; D010567:Pertussis Vaccine / Q000009:adverse effects*; D013997:Time Factors; D017778:Vaccines, Combined / Q000009:adverse effects*
D015721:Diphtheria-Tetanus-Pertussis Vaccine; D018073:Haemophilus Vaccines; D010567:Pertussis Vaccine; D017778:Vaccines, Combined